Condition: Hepatocellular Carcinoma · Sponsor: Northwestern University
The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.
This description comes directly from the study's public registry record.
Study Coordinator · 3126951301 · cancer@northwestern.edu
Always discuss trial participation with your own doctor first.
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Northwestern Medicine Kishwaukee Hospital | DeKalb, Illinois, United States | Recruiting |
| Northwestern Medicine Delnor Hospital | Geneva, Illinois, United States | Recruiting |
| Northwestern Medicine Grayslake Outpatient Center | Grayslake, Illinois, United States | Recruiting |
| Northwestern Medicine Lake Forest Hospital | Lake Forest, Illinois, United States | Recruiting |
| Northwestern Medicine Orland Park | Orland Park, Illinois, United States | Recruiting |
| Northwestern Medicine Warrenville | Warrenville, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05620771